We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+2.99%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$671M
AUM Growth
-$17.2M
Cap. Flow
+$158M
Cap. Flow %
23.52%
Top 10 Hldgs %
38.66%
Holding
127
New
38
Increased
29
Reduced
15
Closed
24

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$30M
2
FRC
First Republic Bank
FRC
+$28.6M
3
EOLS icon
Evolus
EOLS
+$21.6M
4
NVO
Novo Nordisk
NVO
+$19.1M
5
ACET icon
Adicet Bio
ACET
+$15.1M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$14.5M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$12.6M
3
ALBO
Albireo Pharma Inc
ALBO
+$8.9M
4
HRTX icon
Heron Therapeutics
HRTX
+$8.03M
5
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$6.72M

Sector Composition

Rank Sector Weight
1 Healthcare 91.26%
2 Financials 6.75%
3 Real Estate 0.31%
4 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
101
Nektar Therapeutics
NKTR
$2.58B
$98.1K 0.01%
9,307
-1,639
-15% -$49.6K
EQ icon
102
Equillium
EQ
$133M
$64.7K 0.01%
+88,568
New +$84.7K
TECX
103
Tectonic Therapeutic
TECX
$606M
$37.6K 0.01%
+3,134
New +$43.6K
ALDX icon
104
Aldeyra Therapeutics
ALDX
$93.5M
– –
-272,293
Closed -$1.9M
ASND icon
105
Ascendis Pharma A/S
ASND
$16.8B
– –
-36,090
Closed -$4.41M
AUPH icon
106
Aurinia Pharmaceuticals
AUPH
$2.11B
– –
-200,000
Closed -$864K
BABA icon
107
Alibaba
BABA
$308B
– –
-50,000
Closed -$4.4M
BEAM icon
108
Beam Therapeutics
BEAM
$2.84B
– –
-95,000
Closed -$3.72M
BNTX icon
109
BioNTech
BNTX
$23.5B
– –
-30,000
Closed -$4.51M
BPMC
110
DELISTED
Blueprint Medicines
BPMC
– –
-40,000
Closed -$1.75M
CLDX icon
111
Celldex Therapeutics
CLDX
$3.28B
– –
-21,192
Closed -$945K
CRSP icon
112
CRISPR Therapeutics
CRSP
$5.17B
– –
-10,000
Closed -$407K
CYTK icon
113
Cytokinetics
CYTK
$10.4B
– –
-110,000
Closed -$5.04M
GOSS icon
114
Gossamer Bio
GOSS
$87M
– –
-100,000
Closed -$217K
LEGN icon
115
Legend Biotech
LEGN
$4.01B
– –
-60,000
Closed -$3M
MLTX icon
116
MoonLake Immunotherapeutics
MLTX
$1.55B
– –
-245,714
Closed -$2.58M
OBIO icon
117
Orchestra BioMed
OBIO
$254M
– –
-392,500
Closed -$3.92M
OLMA icon
118
Olema Pharmaceuticals
OLMA
$1.05B
– –
-318,926
Closed -$781K
RLMD icon
119
Relmada Therapeutics
RLMD
$527M
– –
-100,000
Closed -$349K
TCRX icon
120
TScan Therapeutics
TCRX
$52M
– –
-514,655
Closed -$798K
OKUR
121
OnKure Therapeutics
OKUR
$168M
– –
-3,059
Closed -$71.3K
MRTX
122
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-60,000
Closed -$2.72M
SIOX
123
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-2,000,000
Closed -$870K
CNCE
124
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-1,150,000
Closed -$6.72M
ALBO
125
DELISTED
Albireo Pharma Inc
ALBO
– –
-411,968
Closed -$8.9M
2 3 4
5
6

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Tang Capital Management held 127 positions worth $671M, down 2.5% from $688M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tang Capital Management deployed $158M of net new capital in Q1 2023, opening 38 new positions and adding to 29 existing holdings. Its largest new stake was First Republic Bank: 278,759 shares worth $3.9M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 98% a quarter earlier, followed by Financials and Real Estate.

On the sell side, the largest reduction was AnaptysBio, an estimated $14.5M trimmed.

  • Tang Capital Management's largest Q1 2023 buy was First Republic Bank: 278,759 shares worth $3.9M.
  • Tang Capital Management added most to bluebird bio in Q1 2023, an estimated $30M increase.
  • Tang Capital Management's biggest Q1 2023 reduction was AnaptysBio, cutting an estimated $14.5M.
  • Tang Capital Management fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $8.9M.
  • Tang Capital Management's ten largest holdings make up 39% of its $671M portfolio in Q1 2023.
  • Tang Capital Management opened 38 new positions and closed 24 in Q1 2023.
  • Tang Capital Management's portfolio value fell 2.5% quarter-over-quarter to $671M.

Based on Tang Capital Management's 13F filing for Q1 2023, filed 15 May 2023.